Business
Why the Opthea (ASX:OPT) share price is soaring 11% today
The Opthea Ltd (ASX: OPT) share price is soaring in morning trade, up 11.36% trading at $1.72 at the time of writing.
We take a look at the ASX healthcare share’s latest drug trial announcement.
What did Opthea announce?
The Opthea share price has rocketed today after the company announced Phase 3 trials of its OPT-302 retinal disease treatment drug have started. OPT-302 is the Opthea’s “first-in-class VEGF-C/D ‘trap’ inhibitor”.
The company said it had treated its first patient, in the US state of Maryland, for neovascular age-related macular degeneration (AMD).
The clinical-stage biopharmaceutical company is conducting two simultaneous multi-centre randomised Phase 3 trials. Both clinical studies will enrol around 990…
-
General21 hours agoA feeling of calm before the storm descends on Tasmanian politics following motion of no-confidence in Jeremy Rockliff
-
Noosa News20 hours agoForty years inside a Brisbane second-hand store
-
Business24 hours agoWhat did Macquarie’s “FOMO Meter” reveal about the stock market in May?
-
Noosa News22 hours agoNow Open: The Force Is Strong with Australia’s First-Ever ‘Star Wars’ Cafe, Which Is Serving Up Blue Milk at Melbourne Museum